The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Eli Lilly is still in the early stages of its growth ... And while current shareholders may secure a good profit by selling it today, unless they need the money for other reasons, there's no ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes ... after the company said it expects to generate an adjusted 2025 profit of $22.50 a share to $24 a share in 2025, compared with the FactSet ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

TransCelerate BioPharma (TransCelerate), a global nonprofit organization dedicated to improving the health of patients by accelerating and simplifying the clinical R&D process, has released its 2024 ...